NYU School of Medicine's Kaplan Comprehensive Cancer Center

Summary

NYU School of Medicine's Kaplan Comprehensive Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Ovarian Cancer, Brain Tumor, Lymphoma and other specialties. NYU School of Medicine's Kaplan Comprehensive Cancer Center is involved with conducting 273 clinical trials across 219 conditions. There are 6 research doctors associated with this hospital, such as Paul Oberstein, MD, Janice M. Mehnert, Kristen Spencer, MD, and Elaine Shum, MD.

Top PIs

Clinical Trials running at NYU School of Medicine's Kaplan Comprehensive Cancer Center

Lung Cancer

Non-Small Cell Lung Cancer

Breast Cancer

Bladder Cancer

Pancreatic Cancer

Usher syndrome

Small Cell Lung Cancer

Locoregional Recurrence

Transitional Cell Carcinoma

REGN5093

for Lung Cancer

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body

Recruiting

1 award

Phase 1 & 2

5 criteria

Biomarker Screening

for Lung Cancer

RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer. PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.

Recruiting

1 award

N/A

10 criteria

Divarasib + Pembrolizumab

for Non-Small Cell Lung Cancer

This trial is testing a new drug called divarasib along with other cancer treatments. It focuses on people with advanced or metastatic non-small cell lung cancer. The study aims to see how divarasib moves through the body, its safety, and if it helps fight the cancer.

Recruiting

1 award

Phase 1 & 2